HBI-8000

HBI-8000 (tucidinostat) is an oral pill that blocks histone deacetylases, enzymes that keep tumor-suppressor genes silenced. HUYABIO International is testing it in a Phase 3 trial combined with Bristol Myers Squibb's nivolumab in patients with unresectable or metastatic melanoma. The same molecule is already approved in China for two indications (relapsed or refractory peripheral T-cell lymphoma since 2014, and HR-positive HER2-negative breast cancer in combination with an aromatase inhibitor since 2019) and in Japan for peripheral T-cell lymphoma since 2021, so the safety profile is well mapped in Asia [1][3][4][5][9]. The Western bet: layering an epigenetic drug on top of a checkpoint inhibitor will pry open tumors that nivolumab alone cannot reach, particularly cold tumors that hide from immune cells. The Phase 3 trial (NCT04674683) is supported by a single-arm Phase 2 in Chinese melanoma patients combining tucidinostat with toripalimab (another anti-PD-1) that showed a 27.8% confirmed response rate, with a stronger signal in acral and mucosal melanoma subtypes [2][10]. The Phase 3 is active but no longer recruiting, with results expected to drive HUYABIO's first US registration push if positive [2].

This is an approved drug being repositioned for a new indication, not a brand-new molecule. Tucidinostat was first approved in China in December 2014 under the brand Epidaza for relapsed or refractory peripheral T-cell lymphoma [4]. In November 2019, the China NMPA expanded the label to include hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor for post-menopausal patients previously treated with endocrine therapy [9]. Japan cleared the molecule in June 2021 as Hiyasta for peripheral T-cell lymphoma via Eisai [5]. China added a third indication in 2024 with the approval of chidamide plus R-CHOP for diffuse large B-cell lymphoma [11]. HUYABIO International licensed Western rights from Shenzhen Chipscreen Biosciences and is running the global Phase 3 melanoma program in collaboration with Bristol Myers Squibb, which provides Opdivo (nivolumab) clinical supply [12]. NCT04674683 enrolled approximately 480 patients (the protocol target, including a roughly 30-patient open-label cohort of adolescents and patients with new progressive brain metastases) and is currently listed as active but not recruiting, meaning enrollment has closed and patients are being followed for the primary endpoint [2]. The dose is HBI-8000 30 mg orally twice weekly, taken approximately 30 minutes after a meal, combined with standard-dose nivolumab; this is the same total weekly exposure used in the approved Asian labels [2]. The trial was supported by a single-arm Chinese Phase 2 of tucidinostat plus toripalimab in unresectable or metastatic melanoma presented at ASCO 2024, which reported a 27.8% confirmed objective response rate and an acceptable safety profile [10]. No public FDA breakthrough therapy designation has been disclosed for the melanoma indication, and no priority review or orphan status applies, because metastatic melanoma is not a rare disease. Expected readout timing has not been publicly committed by HUYABIO, but with active-not-recruiting status and an event-driven primary endpoint typical of melanoma combination trials, a readout in 2026 or 2027 is plausible. Whether the protocol includes a pre-specified interim analysis is not disclosed in the public registry. The drug already has labels in three indications in China, which de-risks manufacturing and chemistry/controls work for any future US filing.

Inside every cell, DNA is wound around protein spools called histones. When small chemical tags called acetyl groups sit on the histones, the DNA is loose and genes can be read. Enzymes called histone deacetylases (HDACs) strip those tags off, the DNA tightens up, and genes go silent. Cancer cells abuse this system to switch off tumor suppressor genes and immune recognition genes that would otherwise hold them in check. HBI-8000 blocks four members of the HDAC family, HDAC1, HDAC2, HDAC3, and HDAC10, with a strong preference for the class I enzymes (HDAC1, 2, 3) that sit in the nucleus and do most of the silencing work [1]. The mechanism is well-validated in T-cell lymphoma, where the same drug is already approved and where the response rate as a single agent was about 28% in the Chinese registration program [1]. The bigger bet in melanoma is the combination logic with nivolumab. HDAC inhibition is hypothesized to do three things at once. First, it re-expresses MHC class I on tumor cells - these are the cell-surface molecules that display fragments of internal proteins to killer T-cells, so a tumor cell that has silenced its MHC class I is essentially invisible to the immune system, and HDAC inhibition restores that visibility. Second, it shrinks the population of suppressor cells (regulatory T-cells, which are a normal immune brake that tumors exploit, and myeloid-derived suppressor cells, an immature bone-marrow-derived cell type that surrounds tumors and blocks T-cell attack). Third, it increases production of chemokines that recruit T-cells into the tumor. Translation: take a cold tumor that nivolumab cannot crack and warm it up enough for the checkpoint inhibitor to work. The preclinical case is solid: in a B16F10 mouse melanoma model, HDAC inhibition combined with PD-1 blockade slowed tumor growth and extended survival compared with either treatment alone, and HDAC inhibitors are known to upregulate PD-L1 (the very ligand nivolumab targets) in melanoma cells [6]. Whether this translates to a survival benefit in real human melanoma patients is what NCT04674683 will answer.

NCT04674683 is a randomized, double-blind, placebo-controlled Phase 3 study comparing oral HBI-8000 30 mg twice weekly plus intravenous nivolumab against placebo plus nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors. Approximately 480 patients are enrolled across sites in the US, Europe, Australia, New Zealand, and Japan, and the trial is now active but not recruiting [2][12]. The primary endpoint is overall survival, supported by progression-free survival and objective response rate. A separate open-label cohort enrolls adolescents (≥12 years) and patients with new, progressive brain metastases, which is why the database tags this node with brain tumors as a therapeutic area, though primary brain tumors are not in scope. The Phase 3 was justified by a single-arm Chinese Phase 2 of tucidinostat plus toripalimab (a Chinese anti-PD-1) in metastatic melanoma, which reported a confirmed objective response rate of 27.8% (95% CI 9.7-53.5%), a disease control rate of 61.1%, and a median progression-free survival of 4.1 months [10]. The response rate was notably stronger in the acral subtype (50%) and modest in mucosal melanoma (22%), both of which are more common in Asian populations than the cutaneous BRAF-mutant melanomas typical in Western patients; this is the central translational question the Phase 3 must answer. The design has strengths and weaknesses. Strengths: a hard endpoint of overall survival, placebo control, sample size large enough to detect a meaningful hazard ratio, and a real standard-of-care comparator arm rather than a strawman. Weaknesses: no biomarker selection, meaning HBI-8000 must work across an unselected melanoma population that mixes BRAF-mutant patients who often go to targeted therapy first, PD-L1-high patients who already do well on nivolumab alone, and subtypes where epigenetic priming is unlikely to matter. The combination must beat single-agent nivolumab on overall survival by enough to clear both regulatory and commercial bars, and the bar is high because nivolumab plus ipilimumab and nivolumab plus relatlimab already occupy the combination niche.

The model gives this drug an 11% chance of eventually being approved. That figure starts from a baseline of about 48% for Phase 3 drugs in this area, then adjusts based on ten specific facts about the trial and sponsor. The estimate is pulled down mainly by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak earlier-phase results, and a randomized trial design. The remaining factors were close to average for this stage, so they didn't move the number much.

Efficacy risk dominates. The HDAC class has failed repeatedly in solid tumors. Entinostat, the closest comparator (a class I-selective benzamide HDAC inhibitor like HBI-8000), missed its Phase 3 E2112 trial in hormone-receptor-positive breast cancer with exemestane despite a positive Phase 2 signal [8]. Notably, tucidinostat itself succeeded in essentially the same indication in China (HR-positive HER2-negative breast cancer with an aromatase inhibitor) [9], which is either evidence that the Chinese trial design was easier to clear or evidence that subtle class differences matter - both readings have precedent. Multiple HDAC plus checkpoint inhibitor combination Phase 2 studies in melanoma, lung cancer, and kidney cancer have produced response rates that do not clearly beat the checkpoint inhibitor alone. The biological hypothesis is plausible. The field's batting average is poor. Safety risk is real but manageable. The tucidinostat label in China and Japan flags thrombocytopenia, neutropenia, fatigue, and QT interval prolongation (a heart-rhythm delay that raises arrhythmia risk) as the main toxicities [1]. The QT signal matters because some melanoma patients also have cardiac comorbidities or BRAF/MEK pretreatment. Stacking HDAC-driven myelosuppression on nivolumab does not in theory worsen immune-related adverse events, but pneumonitis, colitis, and hepatitis are all possible if HDAC inhibition amplifies T-cell activation non-specifically. Execution risk is moderate. HUYABIO is a US-based privately held biotech with limited late-stage commercial infrastructure, and its current cash position and runway to readout are not publicly disclosed. The Bristol Myers Squibb arrangement is a clinical trial collaboration in which BMS supplies Opdivo only; no co-development, no co-commercialization, and no public option language has been disclosed [12]. A positive trial would therefore most likely trigger a licensing or partnership transaction before HUYABIO attempts independent US commercialization, but there is no automatic mechanism for BMS to acquire the rights. Commercial risk is severe even if the trial reads out positive. First-line melanoma is dominated by nivolumab plus ipilimumab, nivolumab plus relatlimab, and BRAF/MEK combinations. Payers and clinicians need to see a substantial overall survival benefit, not just statistical significance, to displace established regimens.

Worth watching, with skepticism dialed up. The signal to wait for is the NCT04674683 readout, which has not been publicly date-committed but is plausibly 2026 or 2027 given active-not-recruiting status [2]. The specific data point that would change the story: an overall survival hazard ratio of 0.75 or better in the intent-to-treat population (intent-to-treat means all randomized patients are analyzed in the arm they were assigned to, regardless of whether they completed treatment - this is the most conservative and most regulator-friendly way to read a trial). Hazard ratio is the headline number for survival trials: a hazard ratio below 1.0 means the combination arm had lower risk of death at any given moment than the control arm, with 0.75 meaning roughly a 25% reduction in that risk. Anything in the 0.85 to 1.00 range, even if statistically significant, is unlikely to move the standard of care in a crowded first-line melanoma market. HUYABIO International is private, so there is no public stock to trade on this readout, and its financing status is not publicly disclosed, which is itself a risk: a privately-held sponsor without disclosed runway is harder to underwrite than a public counterpart at the same stage. A positive result would almost certainly trigger a licensing or acquisition transaction with a larger oncology player. Bristol Myers Squibb is the obvious counterparty given the nivolumab clinical-supply partnership, but Merck, Roche, or AstraZeneca could plausibly bid if the data show the HDAC plus IO logic works broadly. A negative result would be a meaningful update for the entire HDAC plus checkpoint combination thesis, which is being tested in several other Phase 2 programs across solid tumors, including a tucidinostat plus pembrolizumab study in non-small-cell lung cancer (NCT05141357). Check back in mid-2026 for readout timing guidance and any ESMO or ASCO interim safety data. Until then, this is one of the few remaining well-powered tests of whether epigenetic drugs can open the door for checkpoint inhibitors in solid tumors.